Adjunct strategies to enhance the efficacy of indwelling pleural catheters
- 77 Downloads
Malignant pleural effusion remains a distressing and unfortunately common occurrence. Pleural palliation should be focused on relieving dyspnea with as few procedures as possible. The introduction of the indwelling tunneled pleural catheter has been shown to fulfill these goals; however, it is not without limitations. The ability to potentially combine the results of a long-term pleurodesis procedure without the need for a prolonged hospitalization remains an attractive option. While no large-scale trials have been completed nor is there widespread acceptance, the introduction of “rapid” or “accelerated” pleurodesis procedures, often using tunneled indwelling pleural catheters, have the potential to significantly change the current paradigm of malignant pleural effusion management. This article reviews the current data available for “rapid” and “accelerated” pleurodesis protocols and their outcomes.
KeywordsMalignant pleural effusion Pleurodesis Rapid pleurodesis Accelerodesis Aggressive pleural drainage Indwelling tunneled pleural catheter
Compliance with ethics guidelines
Conflict of interest
Dr. Christopher Gilbert has no conflict of interest to disclose.
Dr. David Feller-Kopman reports personal fees from CareFusion, during the conduct of the study.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
IPC in place with Talc Poudrage (AVI 34138 kb)
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.•Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307:2383–9. This randomized study compared IPCs to talc slury and found no significant differences in relief of dyspnea or quality of life, though the IPC group experienced more adverse events.CrossRefPubMedGoogle Scholar
- 8.••Fysh ETH, Tremblay A, Feller-Kopman D, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. CHEST J. 2013;144:1597–602. This is the largest study investigating the risk of infection using IPCs in patients with malignant pleural effusions. In 1,021 patients the overall risk of pleural infection was 4.9 %, and overall mortality was 0.29 %. Antibiotics should cover S. aureus and gram negative infections until microbiology is confirmed. In patients who do develop pleural infection, the mortality rate is 6 %.CrossRefGoogle Scholar
- 11.Thomas R, Budgeon CA, Kuok YJ, et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest 2014.Google Scholar
- 14.••Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8. One of the largest studies of IPC, showing efficacy in approximately 90 % of patients. Mean duration of catheter days was 56 days.CrossRefPubMedGoogle Scholar
- 19.Impact of aggressive versus standard drainage regimen using a long term indwelling pleural catheter (ASAP). In: ClinicalTrial.gov, 2014. Accessed 20140918, at https://clinicaltrials.gov/ct2/show/NCT00978939?term=pleurodesis&rank=19.
- 20.Intrapleural catheter daily versus three times a week drainage. In: ClinicalTrials.gov, 2014. Accessed 20140918, at https://clinicaltrials.gov/ct2/show/NCT00761618?term=pleurodesis&rank=26.
- 31.Singapore General Hospital. A prospective, randomized controlled trial for a rapid pleurodesis protocol for the management of pleural effusions. NLM Identifier: NCT00758316. Bethesda (MD): In: ClinicalTrials.gov; 2014.Google Scholar
- 32.Active Pleurodesis Catheter. 2012. Accessed 18 Sept 2014, at http://www.sumobrain.com/patents/wipo/Active-pleurodesis-catheter/WO2012161954.html.